Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

A genome-wide siRNA screen reveals positive and negative regulators of the NOD2 and NF-κB signaling pathways.

Warner N, Burberry A, Franchi L, Kim YG, McDonald C, Sartor MA, Núñez G.

Sci Signal. 2013 Jan 15;6(258):rs3. doi: 10.1126/scisignal.2003305.

2.

A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion.

Warner N, Burberry A, Pliakas M, McDonald C, Núñez G.

J Biol Chem. 2014 Oct 10;289(41):28213-24. doi: 10.1074/jbc.M114.574756. Epub 2014 Aug 28.

3.

Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice.

Dugan J, Griffiths E, Snow P, Rosenzweig H, Lee E, Brown B, Carr DW, Rose C, Rosenbaum J, Davey MP.

J Immunol. 2015 Jan 1;194(1):349-57. doi: 10.4049/jimmunol.1402330. Epub 2014 Nov 26.

4.

Z-100, extracted from Mycobacterium tuberculosis strain Aoyama B, promotes TNF-α production via nucleotide-binding oligomerization domain containing 2 (Nod2)-dependent NF-κB activation in RAW264.7 cells.

Katsunuma K, Yoshinaga K, Ohira Y, Eta R, Sato T, Horii T, Tanaka T, Takei M, Seto K.

Mol Immunol. 2015 Mar;64(1):218-27. doi: 10.1016/j.molimm.2014.11.017. Epub 2014 Dec 8.

PMID:
25499802
5.

Nod1 and Nod2 induce CCL5/RANTES through the NF-kappaB pathway.

Werts C, le Bourhis L, Liu J, Magalhaes JG, Carneiro LA, Fritz JH, Stockinger S, Balloy V, Chignard M, Decker T, Philpott DJ, Ma X, Girardin SE.

Eur J Immunol. 2007 Sep;37(9):2499-508.

6.

The molecular chaperone HSP70 binds to and stabilizes NOD2, an important protein involved in Crohn disease.

Mohanan V, Grimes CL.

J Biol Chem. 2014 Jul 4;289(27):18987-98. doi: 10.1074/jbc.M114.557686. Epub 2014 Apr 30.

7.

RNAi screening identifies mediators of NOD2 signaling: implications for spatial specificity of MDP recognition.

Lipinski S, Grabe N, Jacobs G, Billmann-Born S, Till A, Häsler R, Aden K, Paulsen M, Arlt A, Kraemer L, Hagemann N, Erdmann KS, Schreiber S, Rosenstiel P.

Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21426-31. doi: 10.1073/pnas.1209673109. Epub 2012 Dec 3.

8.

MDP-Induced selective tolerance to TLR4 ligands: impairment in NOD2 mutant Crohn's disease patients.

Cantó E, Moga E, Ricart E, Garcia-Bosch O, Garcia-Planella E, Juarez C, Vidal S.

Inflamm Bowel Dis. 2009 Nov;15(11):1686-96. doi: 10.1002/ibd.21013.

PMID:
19572373
9.

NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2.

Yang Y, Yin C, Pandey A, Abbott D, Sassetti C, Kelliher MA.

J Biol Chem. 2007 Dec 14;282(50):36223-9. Epub 2007 Oct 18.

10.

Nod2 and Rip2 contribute to innate immune responses in mouse neutrophils.

Jeong YJ, Kang MJ, Lee SJ, Kim CH, Kim JC, Kim TH, Kim DJ, Kim D, Núñez G, Park JH.

Immunology. 2014 Oct;143(2):269-76. doi: 10.1111/imm.12307.

11.

Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains.

Abbott DW, Yang Y, Hutti JE, Madhavarapu S, Kelliher MA, Cantley LC.

Mol Cell Biol. 2007 Sep;27(17):6012-25. Epub 2007 Jun 11.

12.

Nod2 downregulates TLR2/1 mediated IL1β gene expression in mouse peritoneal macrophages.

Dahiya Y, Pandey RK, Sodhi A.

PLoS One. 2011;6(11):e27828. doi: 10.1371/journal.pone.0027828. Epub 2011 Nov 17.

13.

Mucosal NOD2 expression and NF-kappaB activation in pediatric Crohn's disease.

Stronati L, Negroni A, Merola P, Pannone V, Borrelli O, Cirulli M, Annese V, Cucchiara S.

Inflamm Bowel Dis. 2008 Mar;14(3):295-302.

PMID:
18092345
14.

A role for Erbin in the regulation of Nod2-dependent NF-kappaB signaling.

McDonald C, Chen FF, Ollendorff V, Ogura Y, Marchetto S, Lécine P, Borg JP, Nuñez G.

J Biol Chem. 2005 Dec 2;280(48):40301-9. Epub 2005 Oct 3.

15.

Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing.

Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF, Eckmann L, Karin M.

Science. 2005 Feb 4;307(5710):734-8. Erratum in: Science. 2011 Jul 15;333(6040):288. Science. 2005 Apr 29;308(5722):633.

16.

A novel motif in the Crohn's disease susceptibility protein, NOD2, allows TRAF4 to down-regulate innate immune responses.

Marinis JM, Homer CR, McDonald C, Abbott DW.

J Biol Chem. 2011 Jan 21;286(3):1938-50. doi: 10.1074/jbc.M110.189308. Epub 2010 Nov 19.

17.

Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease.

Wang TT, Dabbas B, Laperriere D, Bitton AJ, Soualhine H, Tavera-Mendoza LE, Dionne S, Servant MJ, Bitton A, Seidman EG, Mader S, Behr MA, White JH.

J Biol Chem. 2010 Jan 22;285(4):2227-31. doi: 10.1074/jbc.C109.071225. Epub 2009 Nov 30.

18.

The crosstalk between TLR2 and NOD2 in Aspergillus fumigatus keratitis.

Wu J, Zhang Y, Xin Z, Wu X.

Mol Immunol. 2015 Apr;64(2):235-43. doi: 10.1016/j.molimm.2014.11.021. Epub 2014 Dec 27.

PMID:
25549945
19.

Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways.

Brosbøl-Ravnborg A, Hvas CL, Agnholt J, Dahlerup JF, Vind I, Till A, Rosenstiel P, Höllsberg P.

Clin Exp Immunol. 2009 Mar;155(3):487-95. doi: 10.1111/j.1365-2249.2008.03850.x. Epub 2008 Dec 15.

20.

TAK1 is a central mediator of NOD2 signaling in epidermal cells.

Kim JY, Omori E, Matsumoto K, Núñez G, Ninomiya-Tsuji J.

J Biol Chem. 2008 Jan 4;283(1):137-44. Epub 2007 Oct 26.

Supplemental Content

Support Center